Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.49 |
| ▸ | PDE4A | P27815 | 14/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6878255 | 0.84 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL25205204 | 0.83 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL825619 | 0.83 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL5557255 | 0.83 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL23326959 | 0.83 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL1193708 | 0.82 | PDE4B (0.72) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL3970137 | 0.81 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL4426112 | 0.79 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL10325021 | 0.79 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL23000601 | 0.78 | PDE4B (0.75) | PDE4BPDE4APDE4CPDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551385-A4 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | CELGENE CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1496878-A4 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORP (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1562586-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORP (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1562586-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1551385-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | Celgene Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1496878-A1 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORPORATION (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1126839-A4 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORP (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004037207-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004034962-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | CELGENE CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003086373-A1 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1126839-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORPORATION (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025777-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNFαLEVELS | CELGENE CORPORATION (US) | 2000-05-11 | — | — | WO | disclosed |